CELL INTELLIGENCE · 肿瘤细胞治疗研究

靶向 Wilms 瘤 1 抗原的树突状细胞疫苗减少髓源性抑制细胞对急性白血病患者临床结局的影响

Impact of Reduction in Myeloid-derived Suppressor Cells by Wilms' Tumor 1-targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Pati

这些发现表明 WT1-DC 疫苗抑制 MDSCs 并改善临床结局。

利用多能干细胞生成的 T 细胞开发免疫细胞疗法

Development of Immune Cell Therapy Using T Cells Generated from Pluripotent Stem Cells.

NKT 细胞许可的体内基于树突状细胞的免疫疗法作为癌症治疗的细胞免疫药物

NKT-Licensed In Vivo Dendritic Cell-Based Immunotherapy as Cellular Immunodrugs for Cancer Treatment.

用于 HLA II 类限制性 TCR 功能性亲合力成熟的新型 NFAT-GFP 报告平台的建立

Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs.

一种新型口服含辅助表位 WT1 蛋白疫苗在小鼠白血病模型中的抗肿瘤活性增强

Enhanced antitumor activity of a novel, oral, helper epitope-containing WT1 protein vaccine in a model of murine leukemia.

与 B. longum 420 相比，B. longum 420/2656 联合治疗进一步加速了依赖于肿瘤中 WT1 特异性 CTL 的抗肿瘤活性。

通过治疗性细胞疫苗重振 AML 患者的先天性和适应性免疫

Reinvigoration of innate and adaptive immunity via therapeutic cellular vaccine for patients with AML.

Wilms 瘤 1 肽负载树突状细胞疫苗治疗复发/难治性急性白血病患者

Wilms' tumor 1 peptide-loaded dendritic cell vaccination in patients with relapsed or refractory acute leukemia.

这些结果表明，基于 DC 的免疫疗法对急性白血病患者是安全且可行的。

利用诱导多能干细胞（iPSC）技术再生抗原特异性 T 细胞

Regeneration of antigen-specific T cells by using induced pluripotent stem cell (iPSC) technology.